Robert Hariri, Celularity CEO (Vivien Killilea/Getty Images for Brain Mapping Foundation)

Celu­lar­i­ty signs on to do con­tract re­search for Re­gen­eron

Celu­lar­i­ty an­nounced Tues­day morn­ing that it will do con­tract re­search for Re­gen­eron on the Tar­ry­town, NY-based com­pa­ny’s “off-the-shelf” CAR-T cell ther­a­pies. Af­ter a rough year, it’s an­oth­er way for Celu­lar­i­ty to fund its busi­ness.

Celu­lar­i­ty de­clined to share the fi­nan­cial de­tails of the con­tract. The ini­tial fo­cus of the work will be Re­gen­eron’s gam­ma delta CAR-T cell ther­a­py that is de­signed to at­tack sol­id tu­mors. Re­gen­eron is part­nered with Adicet Bio on Adicet’s gam­ma delta CAR-T ther­a­py, which they’ve been col­lab­o­rat­ing on since 2016.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.